At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
02595 GENFLEET-B
Not Yet Opened 01-19 16:08:03
30.160
-2.600
-7.94%
High32.780
Low30.100
Vol668.71K
Open32.760
D1 Closing32.760
Amplitude8.18%
Mkt Cap11.16B
Tradable Cap10.19B
Total Shares370.00M
T/O20.83M
T/O Rate0.20%
Tradable Shares338.00M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Loading ...
Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.
GENFLEET-B (02595) Nears Inclusion in Stock Connect: Stable Trading as Key Factor
GENFLEET-B (02595): GFH375 Phase III Trial for Metastatic Pancreatic Cancer Initiated at First Site – World’s First Oral KRAS G12D Inhibitor Monotherapy vs. Chemotherapy Study
HK Stock Movement | GENFLEET-B (02595) Surges Over 8% in Late Trading as GFH375 Tablets Enter Phase III Clinical Trial for Metastatic Pancreatic Cancer
Hong Kong Stock Movement | GENFLEET-B (02595) Recovers Over 9% After Completion of First Patient Enrollment in GFH375 Combination Therapy for Advanced Solid Tumors
GENFLEET-B (02595) Announces First Patient Enrollment in Phase I/II Clinical Trial of Molecular Glue Pan RAS(ON) Inhibitor GFH276 for RAS-Mutant Cancer Treatment
GenFleet Therapeutics (Shanghai) Inc is a China-based company principally engaged in the development of innovative drugs. The Company provides effective new treatment solutions for tumors, autoimmune and inflammatory diseases, covering target discovery, molecular discovery and evaluation, translational science and clinical development, as well as key chemistry manufacturing and controls aspects including formulation research, process development and quality analysis. The Company is mainly engaged in the development of new molecular entities, novel molecular modalities, investigation of molecular process routes and quality standards, and exploration of differentiated clinical development strategies and paths. The Company mainly primarily operates in the domestic and international markets.